Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: A phase I/II study

Anticancer Research

Volumn 23, Issue 1 B, 2003, Pages 617-626

  Hercbergs, Aleck A ^a   Goyal, Lav K ^a   Suh, John H ^a   Lee, Sy ^a   Reddy, Chandana A ^a   Cohen, Bruce H ^a   Stevens, Glen H ^a   Reddy, Sethu K ^a   Peereboom, David M ^a   Elson, Paul J ^a   Gupta, Manjula K ^a   Barnett, Gene H ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Astrocytoma; Brain neoplasms; Hypothyroidism; Insulin like growth factor 1; Thyroid hormones

Indexed keywords

PROPYLTHIOURACIL; SOMATOMEDIN C; TAMOXIFEN; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLIOMA; HUMAN; HYPOTHYROIDISM; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENT CANCER; SURVIVAL RATE; SYMPTOM; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTITHYROID AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; HYPOTHYROIDISM; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; PROPYLTHIOURACIL; TAMOXIFEN; THYROID GLAND; THYROTROPIN;

EID: 0037235850     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Mahaley SM, Mettlin C, Natajaran N, Laws ER Jr and Peace BB: National survey of patterns of care for brain-tumor patients. J Neurosurg 71: 826-836, 1989.
2. Couldwell WT, Antel JP, Apuzzo ML and Yong VW: Inhibition of growth of established human glioma cell lines by modulators of the protein kinase-C system. J Neurosurg 73: 594-600, 1990.
3. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH and Law RE: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345: 43-46, 1994.
4. Couldwell WT, Uhm JH, Antel JP and Yong VW: Enhanced protein kinase c activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery 29: 880-886; discussion 886-887, 1991.
5. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG and Vertosick FT Jr: Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways. J Neurosurg 73: 98-105, 1990.
6. Couldwell WT, Weiss MH, DeGiorgio CM, Hinton DR, Ehresmann GR, Conti PS et al.: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32(3): 485-489; discussion 489-490, 1993.
7. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM and Kaplan MM: Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318: 1557-1563, 1988.
8. Baserga R: Oncogenes and the strategy of growth factors. Cell 79: 927-930, 1994.
9. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R et al.: The 2- insulin-like growth factor 1 receptor protects tumor cells from apoptosis in vivo. Cancer Res 55: 2463-2469, 1995.
10. Sandberg-Nordqvist AC, Stahlbom PA, Reinecke M, Collins VP, von Holst H and Sara V: Characterization of insulin-like growth factor 1 in human primary brain tumors. Cancer Res 53: 2475-2478, 1993.
11. Toms SA, Hercbergs A, Liu J: Kondo S, Haqqi T, Casey G, et al: Antagonist effect on insulin-like growth factor 1 on protein kinase inhibitor-mediated apoptosis in human glioblastoma cells in association with bcl-2 and bcl-xL. J Neurosurg 88: 884-889, 1998.
12. LeRoith D, Baserga R, Helman L and Roberts CT Jr: Insulin-like growth factors and cancer. Ann Intern Med 122: 54-59, 1995.
13. Werner H and Le Roith D: The insulin-like growth factor-1 receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis: Crit Rev Oncog 8(1): 71-92, 1997.
14. Glick RP, Lichtor T and Unterman TG: Insulin-like growth factors in central nervous system tumors. J Neurooncol 35: 315-325, 1997.
15. Valcavi R, Dieguez C, Preece M, Taylor A, Portioli I and Scanlon MF: Effect of thyroxine replacement therapy on plasma insulin-like growth factor-1 levels and growth hormone responses to growth hormone releasing factor in hypothyroid patients. Clin Endocrinol (Oxf) 27: 85-90, 1987.
16. Wolf M, Ingbar S and Moses AC: Thyroid hormone and growth hormone interact to regulate insulin-like growth factor-1 messenger ribonucleic acid and circulating levels in the rat. Endocrinology 125: 2905-2914, 1989.
17. Hercbergs A: Spontaneous remission of cancer-a thyroid hormone-dependent phenomenon? Anticancer Res 19: 4839-4844, 1999.
18. Franklyn JA, Maisonneuve P, Sheppard M, Bettenridge J and Boyle P: Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353: 2111-2115, 1999.
19. Goldman MB, Monson RR and Maloof F: Benign thyroid disease and the risk of death from breast cancer. Oncology 49: 461-466, 1992.
20. Hercbergs A: Does hypothyroidism favor the response to therapy in metastatic breast cancer? Proc Am Society Clinical Oncology 77(7): 20, 1988 (Abstract).
21. Hercbergs A: High tumor response rate to radiation therapy in biochemically hypothyrold patients. Proc Am Assoc Cancer Research 1667(38)248, 1997 (Abstract).
22. Hercbergs A: Hypothyroidism and tumor regression. N Engl J Med 319: 1351-1352, 1988.
23. Reid I, Sharpe I, McDevitt J, Maxwell W, Emmons R, Tanner WA et al.: Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha. Br J Cancer 64: 915-918, 1991.
24. Weijl NI, Van der Harst D, Brand A, Kooy Y, Van Luxemberg S, Schroder J et al: Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyrold antibodies and response to treatment. J Clin Oncol 11: 1376-1383, 1993.
25. Esquenet M, Swinnen JV, Heyns W and Verhoeven G: Trilodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP. Mol Cell Endocrinol 109: 105-111, 1995.
26. Kinoshita S: Effects of hyper- and hypothyroidism on natural defenses against Lewis lung carcinoma and its spontaneous pulmonary metastasis in C57BL/6 mice. Tokushima Journal of Experimental Medicine 38(2): 25-35, 1991.
27. Lin KH, Lin YW, Parkison C and Cheng SY: Stimulation of proliferation by 3,3′,5,- trilodothyronine in poorly differentiated human hepatocarcinoma cells over-expressing beta 1 thyroid hormone receptor. Cancer Lett 85: 189-194, 1994.
28. Mishkin SY, Pollack R, Yalovsky MA, Morris HP and Mishkin S: Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism. Cancer Res 41: 3040-3045, 1981.
29. Yoshida S, Maruo T, Matsuo H and Mochizuki M: Effects of estrogen and thyroid hormone on EGF receptor expression, proliferative activity and SCC production in the CaSki cervical carcinoma cells. Nippon Sanka Fujinka Gakkai Zasshi 47(2): 149-155, 1995.
30. DeFesi CR, Fels ED and Surks MI: L-Triiodothyronine (T3) stimulates growth of cultured GC cells by action early in the G1 period: Evidence for mediation by the nuclear T3 receptor. Endocrinology 116: 2062-2069, 1985.
31. Humes HD, Cieslinski DA, Johnson LB and Sanchez IO: Triiodothyronine enhances renal tubule cell replication by stimulating EGF receptor gene expression. Am J Physiol 262: F540-545, 1992.
32. Barrera-Hernandez G, Park KS, Dace A, Zhan Q and Cheng S: Thyroid hormone-induced cell proliferation in GC cells is mediated by changes in G1 cyclin/cyclin-dependent kinase levels and activity. Endocrinology 140(11): 5267-5274, 1999.
33. Fernandez-Pol JA, Hamilton PD and Klos DJ: Transcriptional regulation of proto-oncogene expression by epidermal growth factor, transforming growth factor beta-1, and trilodothyronine in MDA-468 cells. J Biol Chem 264: 4151-4156,1989
34. Matsuo K, Yamashita S, Niwa M, Kurihara M, Harakawa S, Izumi M et al: Thyroid hormone regulates rat pituitary insulin-like growth factor-1 receptors. Endocrinology 126: 550-554, 1990.
35. Binoux M, Faivre-Bauman A, Lassarre C, Barret A and Tixier-Vidal A: Trilodothyronine stimulates the production of insulin-like growth factors IGF by fetal hypothalamus cells cultured in serum-free medium. Brain Res 353: 319-321, 1985.
36. Fernandez-Pol JA: Modulation of EGF proto-oncogene expression by growth factors and hormones in human breast carcinoma cells. Crit Rev Oncog 2(2): 173-185, 1991.
37. Fernandez-Pol JA, Klos DJ and Hamilton PD: Modulation of transforming growth factor alpha-dependent expression of growth factor receptor gene by transforming growth factor-beta, trilodothyronine, and retinoic acid. J Cell Biochem 41(3): 159-170, 1989.
38. Mukku VR: Regulation of epidermal growth factor receptor levels by thyroid hormone. J Biol Chem 259: 6543-6547, 1984.
39. Orrego H, Blake JE, Blendis LM, Compton KV and Israel Y: Long-term treatment of liver disease with propylthiouracil. N Engl J Med 317: 1421-1427, 1987.
40. Homayoun P, Daher R, Van Lente F, Faiman C and Gupta MK: Immunoradiometric assay measurements of insulin-like growth factor-1 (IGF-1): Comparison with radioimmunoassays using native or des (1-3) IGF-1 as radioligands. J Clin Lab Anal 10: 446-450, 1996.
41. Vertosick FT Jr, Selker RG, Pollack IF and Arena V: The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: Preliminary results in a series of "failed" patients. Neurosurgery 30: 897-903; discussion 902-903, 1992.
42. Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amista P et al: Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: A phase II study. J Clin Oncol 17(2): 645-650, 1999.
43. Quinn KA, Treston AM, Unsworth EJ, Miller M, Vos M, Grimley C et al.: Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 271(19): 11477-11483, 1996.
44. Kaleko M, Rutter WJ and Miller AD: Overexpression of human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 10: 464-473, 1990.
45. Akagi Y, Liu W, Zebrowski B, Xie K and Ellis L: Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-1. Cancer Res 58: 4008-4014, 1998.
46. Toms SA, Hercbergs A, Liu J, Kondo S, Barnett GH, Casey G et al: Thyroid hormone depletion inhibits astrocytoma proliferation via a p53-independent induction of p21 (WAF/CIPI). Anticancer Res 18: 289-293, 1998.
47. Yap N, Yu CL and Cheng SY: Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53. Proc Natl Acad Sci USA 93: 4273-4277, 1996.
48. Vega-Nunez E, Alvarez AM, Menedez-Hurtado A, Santos A and Perez-Castillo A: Neuronal mitochondrial morphology and transmembrane potential are severely altered by hypothyroidism during rat brain development. Endocrinology 138: 3771-3778, 1997.
49. Muller Y, Rocchi E, Lazaro JB and Clos J: Thyroid hormone promotes BCL-2 expression and prevents apoptosis of early differentiating cerebellar granule neurons. Int J Dev Neurosci 13: 871-885, 1995.
50. Kumar MS, Chiang T and Deodhar SD: Enhancing effect of thyroxine on tumor growth and metastases in syngeneic mouse tumor systems. Cancer Res 39: 3515-3518, 1979.
51. Leith J and Hercbergs A: Effects of modulation of thyroid function on the growth and radiation sensitivity of a human colon carcinoma (HT-29). Proc American Assoc Cancer Res 28 (35): 1994 (Abstract).
52. Shoemaker JP and Dagher RK: Remissions of mammary adenocarcinoma in hypothyroid mice given 5-fluorouracil and chloroquine phosphate. J Natl Cancer Inst 62: 1575-1578, 1979.
53. Hercbergs A, Brok-Simoni F, Holtzman F, Bar-Am J, Leith J and Brenner H: Erythrocyte glutathione and tumor response to chemotherapy. Lancet 339: 1074-1076, 1992.
54. Hercbergs A and Leith JT: Spontaneous remission of metastatic lung cancer following myxedema coma- an apoptosis-related phenomenon. J Natl Cancer Inst 85(16): 1342-1343, 1993.
55. Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C et al.: Effect of tamoxifen on insulin-like growth factor 1 levels in stage I breast cancer patients. J Nat Cancer Inst 82(21): 1693-1697, 1990.
56. Vonderhaar BK, Tang E, Lyster RR and Nascimento MC: Thyroid hormone regulation of epidermal growth factor receptor levels in mouse mammary glands. Endocrinology 119(2): 580-585, 1956.
57. Won ET, Hess KR, Gleason NI, Jaekle KA, Kyritsis AP, Prados MD, Levin VA and Yung WKA: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572-2578, 1999.